Clik here to view.
Clik here to view.
新たな国際的世論調査で超低ニコチン紙巻きたばこに対する圧倒的な支持が明らかに
米ニューヨーク州クラレンス （ビジネスワイヤ） — タバコの有害性低減と大麻研究に傾注する植物バイオテクノロジー企業の22ndセンチュリー・グループ（NYSE...
View ArticleClik here to view.
メルク、がん個別化治療を推進するワールドワイド・イノベーティブ・ネットワーク（WIN）コンソーシアム（パリ）に加入
パリ & 独ダルムシュタット （ビジネスワイヤ） —...
View ArticleClik here to view.
New Study Compares Performance of Masimo Next Generation SedLine® Patient...
GENEVA Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2017 in Geneva, Switzerland. In the study, researchers at University Medical Center Groningen,...
View ArticleClik here to view.
New Randomized Trial Shows ReCell® Heals Donor Sites Faster
VALENCIA, Calif. & PERTH, Australia & CAMBRIDGE, England Deploying a suspension of cells generated from a ReCell® medical device onto a skin donor site can speed up healing by 30.7% and...
View ArticleClik here to view.
Green Cross Transforms Procurement with SAP Ariba
SEOUL, South Korea Green Cross Corporation (Green Cross), is out to cure the ills of a fragmented, manual procurement process and build a healthy supply chain. And the company will use solutions...
View ArticleClik here to view.
Navidea Enters Exclusive License and Distribution Agreement For India with...
DUBLIN, Ohio Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) (“Navidea”), a company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics,...
View ArticleClik here to view.
Seqirus Announces Next Major Advancement in Cell-Based Influenza Vaccine...
HOLLY SPRINGS, N.C. Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, today announced the next major advancement in the use of cell-based technology at its state-of-the...
View ArticleClik here to view.
新しい研究でマシモの次世代SedLine®患者状態指標（PSi）の麻酔中における性能をオリジナルPSiと比較
ジュネーブ （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、スイスのジュネーブで開催された2017年欧州麻酔学会議（Euroanaesthesia 2017）で報告されたアブストラクトの知見を発表しました。研究ではオランダのフローニンゲン大学医療センターの研究者らが、プロポフォールまたはセボフルランによる麻酔下の患者で、Masimo...
View ArticleClik here to view.
Manhattan Scientifics Announces Successful Completion of its Affiliate...
NEW YORK Manhattan Scientifics Inc. (MHTX), Imagion Biosystems (IBX) and the National Institute of Health (NIH) collectively have invested over $20M to develop and commercialize the cancer...
View ArticleClik here to view.
新研究比较Masimo下一代SedLine®患者状态指数(PSi)与原初Psi在麻醉期间的性能
日内瓦 (美国商业资讯) — Masimo (NASDAQ: MASI)今天发布了瑞士日内瓦召开的Euroanaesthesia 2017 上呈报的一篇摘要的发现。在该研究中，荷兰格罗宁根大学医疗中心的研究者比较了异丙酚和七氟烷麻醉患者在Masimo SedLine®...
View ArticleClik here to view.
Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from two Phase 1/2 clinical trials evaluating NINLARO™ (ixazomib) in patients with...
View ArticleClik here to view.
Clik here to view.
Samsung Bioepis’ Imraldi® (Adalimumab) Recommended for Approval by European...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on Imraldi®,...
View ArticleClik here to view.
Acelity Strengthens Global Commercial Leadership; Names Ramesh Subrahmanian...
SAN ANTONIO Acelity L.P. Inc., a leading global advanced wound care company, today announced Ramesh Subrahmanian will join the company as President for the International region and member of the...
View ArticleClik here to view.
Genentech’s Emicizumab Showed Positive Results in Phase III Studies (HAVEN 1...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive data from the primary analysis of the Phase III HAVEN 1 study in adults and...
View ArticleClik here to view.
Takeda and Biological E. Limited Announce Partnership to Develop Low-Cost...
OSAKA, Japan & HYDERABAD, India Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”) and Biological E. Limited (“BE”) today announced that they have entered into a collaboration whereby...
View ArticleClik here to view.
Clik here to view.
武田呈报NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者及维持治疗的1/2期研究数据
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，两项评估NINLARO™ (ixazomib)用于新诊断多发性骨髓瘤患者的1/2期临床试验的数据将在欧洲血液学会(EHA) 2017年年会上口述呈报，时间分别是中欧夏令时6月24日星期六上午11:45 – 12和6月25日星期日上午8:15 –...
View ArticleClik here to view.
武田薬品、初発多発性骨髄腫患者および維持療法でニンラーロ（イキサゾミブ）を検討する第1／2相試験のデータを発表
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View Article